22
Apr
2019
Tag: Medtech / Diagnostics
25
Feb
2019
Bionest
Artificial Intelligence and Image-Based Diagnostic Tools
We have recently been hearing much about “machine learning” and “artificial intelligence” (A.I.). While many tend to use the two terms almost interchangeably, there is a distinct difference between the two. Machine learning, also known as “deep learning,” is a field of applied mathematics that uses algorithms and statistical models to build predictive systems...
22
Oct
2018
Bionest
Innovations in Electronic Health Records
Increasingly, hospital and health systems have moved from paper charts to electronic health records (EHRs). EHRs offer ways to streamline clinical workflows, reduce medical errors and increase patient safety, and provide stronger support for clinical decision-making. However, linking such records from different locations for the same patient has proved problematic in many cases, leading to...
10
May
2018
Bionest
BIO2018, here we come: Real-time oncology and biomarkers for Alzheimer’s disease
The BIO International Convention is a huge gathering each year, as around 15-18,000 representatives from across industry and around the world get together to discuss policy, partnering, and product development over the course of four days. This year’s event, to be held in Boston from June 4 – 7, should be no exception. BIO has...
21
Aug
2017
Bionest
New Developments on the Alzheimer’s Disease Diagnostic Front — Part I
In July, we attended the Alzheimer’s Association International Conference in London. The big news at the meeting was on the diagnostics front. In the aftermath of the recent string of trial failures, diagnostic tools have become a critical area of focus, in the hopes that patient diagnosis and selection can be improved. Accurately diagnosing...
3
Apr
2017
Bionest
National Academies of Science and Medicine Cautiously Endorse Some Germline Gene Editing — In the Future
In February the National Academy of Sciences and the National Academy of Medicine issued a new report on the technical, social and regulatory concerns surrounding gene editing, entitled, “Human Genome Editing: Science, Ethics, and Governance.” Authored by a 22 member panel of scientists, ethicists, lawyers, physicians and geneticists from around the world, the report...
21
Mar
2017
Bionest
Alzheimer’s Disease Part Two: Effecting Change – The Need for Validated Biomarkers of Risk and Response
We recently wrote about the continued, costly failure of Alzheimer’s disease drugs, often occurring in Phase 3 clinical development. Of 244 compounds tested from 2002 to 2012, only one gained approval. Today there are four compounds on the market for Alzheimer’s disease (of six total approved since research began), all aimed at treating symptoms rather...
2
Mar
2017
Bionest
Chan Zuckerberg Initiative Makes First Bio Research Awards
Last fall, the Chan Zuckerberg Initiative announced plans to invest $3 billion over 10 years in scientific efforts with an ambitious long-range aim to “cure, prevent or manage” all diseases. As a first part of that effort, they directed $600 million towards the establishment of the CZ Biohub in San Francisco’s Mission Bay neighborhood. This...
21
Dec
2016
Bionest
21st Century Cures Act Heads for Signing, with Aim of Boosting Research and Easing Drug Approvals
On December 13, President Barack Obama signed the 21st Century Cures Act. The landmark bi-partisan health and science bill, which passed the U.S. Senate by a vote of 94 to 5, provides $6.3 billion in funding over 10 years, including $4.8 billion to the National Institutes of Health in support of such programs as...
8
Dec
2016